Protein microarrays: Molecular profiling technologies for clinical specimens

Authors

  • Virginia Espina,

    Corresponding author
    1. FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    • National Cancer Institute, Building 10 Room B1B53, 9000 Rockville Pike, Bethesda, MD 20892, USA Fax: +1-301-402-0043
    Search for more papers by this author
  • Arpita I. Mehta,

    1. FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    2. FDA-NCI Clinical Proteomics Program, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Search for more papers by this author
  • Mary E. Winters,

    1. FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Search for more papers by this author
  • Valerie Calvert,

    1. FDA-NCI Clinical Proteomics Program, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Search for more papers by this author
  • Julia Wulfkuhle,

    1. FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Search for more papers by this author
  • Emanuel F. Petricoin III,

    1. FDA-NCI Clinical Proteomics Program, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Search for more papers by this author
  • Lance A. Liotta

    1. FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Search for more papers by this author

Abstract

Proteomics, the study of protein function within biologic systems, will further our understanding of cancer pathogenesis. Coupled with transcript profiling, proteomics can herald the advent of molecular therapy tailored to the individual patient's neoplasm. Protein microarrays, one emerging class of proteomic technologies, have broad applications for discovery and quantitative analysis. This technology is uniquely suited to gather information about the post-translational modifications of proteins reflecting the activity state of signal pathways and networks. Protein microarrays now make it feasible to conduct signal network profiling within cellular samples. Nevertheless, to be successful, design and use of protein microarrays must take into consideration enormous analytical challenges. A subclass of protein microarrays, Reverse Phase Arrays, created to meet these challenges, has been optimized for use with tissue specimens, and is now in use for the analysis of biopsy samples for clinical trial research.

Ancillary